Ernexa Therapeutics Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2017 | $-466.0K | $-563.0K | $97.0K | $117.0K |
| Jun 2017 | $3.3M | $3.0M | $242.0K | $117.0K |
| Sep 2017 | $-1.8M | $-2.0M | $223.0K | $113.0K |
| Mar 2018 | $-120.0K | $-289.0K | $169.0K | $117.0K |
| Jun 2018 | $359.0K | $248.0K | $111.0K | $134.0K |
| Sep 2018 | $289.0K | $278.0K | $11.0K | $117.0K |
| Mar 2019 | $780.0K | $739.0K | $41.0K | $59.0K |
| Jun 2019 | $559.0K | $521.0K | $38.0K | $50.0K |
| Sep 2019 | $422.0K | $390.0K | $32.0K | $63.0K |
| Mar 2020 | $-1.9M | $-1.9M | $4.5K | $22.7K |
| Jun 2020 | $-2.2M | $-2.2M | $21.7K | $43.0K |
| Sep 2020 | $-2.4M | $-2.4M | $0 | $53.0K |
| Mar 2021 | $-3.4M | $-3.4M | $0 | $419.0K |
| Jun 2021 | $-6.8M | $-6.8M | $0 | — |
| Sep 2021 | $-6.4M | $-6.4M | $7.0K | — |
| Mar 2022 | $-5.4M | $-5.5M | $46.0K | $1.2M |
| Jun 2022 | $-4.0M | $-4.2M | $187.0K | — |
| Sep 2022 | $-6.1M | $-6.2M | $43.0K | — |
| Mar 2023 | $-6.0M | $-6.0M | $0 | $689.0K |
| Jun 2023 | $-3.9M | $-3.9M | $0 | — |
| Sep 2023 | $-5.8M | $-5.8M | $0 | — |
| Mar 2024 | $-3.7M | $-3.8M | $101.0K | $282.0K |
| Jun 2024 | $-2.3M | $-2.5M | $249.0K | — |
| Sep 2024 | $-6.3M | $-6.3M | $19.0K | — |
| Mar 2025 | $-2.1M | $-2.1M | — | $502.0K |
| Jun 2025 | $-2.5M | $-2.5M | — | — |
| Sep 2025 | $-1.3M | $-1.3M | — | — |
| Mar 2026 | $-2.3M | $-2.3M | $2.0K | $309.0K |
| Jun 2026 | $-4.2M | $-4.2M | $3.0K | — |